Medication for prevention and treatment of free radical pathology in animals

FIELD: veterinary medicine.

SUBSTANCE: medication for the prevention and treatment of Pathology findings in animals contains 3.0-5.0 mas.% of phenyl-tert-butilnitrona, 1.0-2.0 mas.% β-carotene, 7.5-10.5 mas.% 2.6-ditretbutil-4-nonylphenol, 10.0-15.0 mas.% of 2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo-(3,3,0)-oktadyselenon-3.7, 5.0-9.0 mas.% Solutol HS15, 0.2-0.4 mas.% Polyvinylpyrrolidone and water for injection (the rest).

EFFECT: increasing the stress resistance of the organism, reducing toxicity and increased ease of use and dosage.

dwg 6 7 ex



Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.

EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.

7 cl, 11 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves chelation of ferric (III) ions both in vivo, and in vitro with using 2-ethyl-6-methyl-3-hydroxypyridine succinate (Mexidol) to produce a stable stained complex having a high molecular weight and a complex (organic-inorganic) composition not identified among the known compounds.

EFFECT: high effectiveness of the chelation process and low toxicity of Mexidol that makes it promising for biomedical application.

4 dwg, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of organic chemistry, namely to novel compound - 5(6)-nitro-1-(thietanyl-3)-2-ethoxybenzimidazole, inhibiting peroxidation of lipids.

EFFECT: novel compound, possessing useful biological properties, has been obtained.

2 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a mixture of two structural isomers: 2,6-di(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-methylphenol and its diastereomers, and 2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-6-(2,2,1-trimethylbicyclo[2.2.1]hept-5-yl)-4-methylphenol, and their diastereomers with the ratio of the first and second structural isomer isomers from 60:40 wt % to 95:5 wt %.

EFFECT: extension of the arsenal of means, possessing simultaneously haemorheological, anti-aggregate, anti-thrombogenic, retinoprotecting, endothelium-protecting, neuroprotecting, anti-arrhythmia and anti-ischemic activity, enhancing the cerebral blood flow.

4 dwg, 20 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: what is presented is using Histochrom (same as echinochrome A or pentahydroxyethyl naphthoquinone) as an agent able to prevent pulmonary fibrosis developed under cytostatic agents. The invention can be used for the pharmacological prevention and correction of the pulmonary tissue disorders caused by administering the cytostatic agents.

EFFECT: preventing hypertrophy of interalveolar connective tissue in the lungs associated with administering bleomycin.

4 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 8·1017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.

EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.

7 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.

EFFECT: invention provides a new tablet form of NADH.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.

EFFECT: implementing the above application.

6 cl, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-1-(1,1-dioxothietanyl-3)-2-chlorobenzimidazole of formula (I) , earlier known as the means with broncholytic and spasmolytic activity, as the means, inhibiting peroxide oxidation of lipids.

EFFECT: realisation of the claimed purpose.

1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of pharmaceutics and medicine and deals with composition, possessing property to stimulate antimicrobial defence by increasing expression of endogenous β-defensins, containing strain B. longum NCC 2705, depositary number CNCM 1-2618, with said strain being brought, at least, partially into non-replicable condition by thermal inactivation, processing , at least, about 70°C. Method of stimulating endogenous antimicrobial activity of mammal by increasing expression of endogenous β-defensins, includes introduction of claimed composition.

EFFECT: group of inventions provides increase of efficiency in comparison with live strains.

12 cl, 2 dwg

FIELD: chemistry.

SUBSTANCE: method includes treating crushed Echinacea purpurea (L.) Moench roots and rhizome with steam, extraction with ethyl alcohol, then steeping, stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench roots and rhizome, after draining a portion of the extract, adding ethyl alcohol to the treated material, draining the whole extract; extracting crushed Echinacea purpurea (L.) Moench herbs with ethyl alcohol, steeping, then stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench herbs, after draining a portion of the extract, adding ethyl alcohol to the treated herbs, draining the whole extract; all obtained extracts are mixed, cooled and filtered under certain conditions. An Echinacea purpurea (L.) Moench tincture. Use of the method to obtain an Echinacea purpurea (L.) Moench tincture.

EFFECT: method preserves the biological activity of components of the tincture and medicinal properties.

3 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to means, possessive immunomodulating action. Method of human immunomodulation by application of live suspension of chlorella of strain Chlorella vulgaris IGF No C-111 with concentration 8-10 millions cell/ml in quantity 200 ml per day for adult human.

EFFECT: method makes it possible to increase human immunity effectively.

7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns an adjuvant immunogenic composition containing meningococcal lipooligosaccharide (LOS) and serotype 14 pneumococcal capsular saccharide (CS14), wherein CS14 contains tetrasaccharide Galβ1-4GlcNAcβ1-3Galβ1-4Glc, while LOS is free from tetrasaccharide Galβ1-4GlcNAcβ1-3Galβ1-4Glc. The group of inventions also concerns a method for inducing the immune response in a mammal involving administering the above composition.

EFFECT: group of inventions provides the stronger immune response to CS14 A as compared to wild-type OMV containing LNnT.

15 cl, 4 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to agriculture, particularly to veterinary medicine, and aims at providing the more effective mosquito puncture procedures for the purpose of treating subclinical mastitis in cows by the effect of mosquitoes on biologically active points. That is ensured by the fact that the exposure covers the biologically active points from both sides of a sacral bone by introducing 20 mosquitoes for 4-5 minutes. The procedures are performed four times every 24 hours.

EFFECT: method provides the clinical effectiveness of 93,3% and is less labour-consuming and environmentally safe as compared to the other methods.

FIELD: medicine.

SUBSTANCE: invention refers to agriculture, particularly to veterinary medicine, and aims at providing higher clinical effectiveness in latent mastitis in cows. That is ensured by using mosquito's salivary secretions as biologically active substances. To this effect, 20 laboratory mosquitoes are introduced on the skin of the affected udder lobes. The treatment is administered for 3 days every 24h at any time of day.

EFFECT: method provides the 100% clinical effectiveness in latent mastitis, being less labour-consuming and environmentally safe as compared to the other methods.

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and concerns an immunostimulant composition containing a compound of formula I; to a method for enhancing the immune response to an antigen in an individual, involving administering the antigen and composition into the individual. Enhancing the immune response can represent enhancing the antibody-mediated immune response, CD4+ T-cell response, CD8+ T-cell response or activating the antigen-presenting cells. What is also presented is a method for enhancing the immune response by administering the antigen and composition containing the compound of formula I intramuscularly.

EFFECT: group of inventions enables achieving enhancing the immune response to the antigen.

24 cl, 7 ex, 13 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a pneumococcal vaccine containing saccharide of 4, 6B, 9V, 14, 18C, 19F and 23F serotypes, separately conjugated with CRM197, and at least one Toll-like receptor-9 (TLR-9) agonist as an adjuvant, wherein the above Toll-like receptor-9 agonist represents CpG-oligonucleotide. Also, the group of inventions concerns using the pneumococcal vaccine for preparing the therapeutic agent for preventing or treating diseases caused by S.pneumoniae; a method for individual's immunisation against the diseases caused by S.pneumoniae infection, involving administering the immunoprotective dose of the vaccine into the above individual.

EFFECT: adding B-class CpG to the conjugated pneumococcal vaccine provides the considerable increase of the proportion of highly responsive patients, good tolerance and cell memory induction in relation to pneumococcal polysaccharides.

45 cl, 9 dwg, 4 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is a group if inventions: a pharmaceutical composition, containing immunologically active enantiomer of a component of the cationic lipid R-DOTAP or S-DOTAP, a method of applying the said enantiomer for induction of an immunostimulating adjuvant effect in the immune system, a method of inducing immune response in a patient with applying thereof and a method of treatment or prevention of a disease in the patient by induction of the immunostimulating adjuvant effect by the lipid.

EFFECT: R-DOTAP and S-DOTAP induced production of cytokines IL-2, IL-8, IL-12, chemokines CCL-5, CCL-19 and tumour regression in mice.

23 cl, 15 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: abdominal paracentesis is performed to remove ascetic fluid to be concentrated and filtered by means of hemodialysis filter and plasma filter. The prepared concentrate is added with human recombinant interleukin-2 in a dose of 500 IU. The concentrate is refused intravenously at a perfusion rate of 60 drops a minute in an amount of 500 ml. On the day following the abdominal paracentesis, the concentrate is introduced again.

EFFECT: method provides effective elimination of hypo- and dysproteinemia in the given category of patients, as well as the correction of immune disorders by using plasma self-proteins and cytokines that enables the further surgical correction of the detected pathology.

3 ex

FIELD: medicine.

SUBSTANCE: invention describes a method for producing Sel-Plex nanocapsules possessing the supramolecular properties by non-solvent addition, characterised by the fact that Sel-Plex is dissolved in dimethyl sulphoxide; the prepared mixture is dispersed in xanthum gum solution used as a nanocapsule shell, in butanol, in the presence of E472c preparation while stirring at 1000 cycles per second; the mixture is added with the precipitator benzol, filtered and dried at room temperature.

EFFECT: simplifying and accelerating the process of nanoencapsulation and ensuring higher weight yield.

4 ex, 12 dwg